<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01464307</url>
  </required_header>
  <id_info>
    <org_study_id>MRZ 60201/SP/3002</org_study_id>
    <secondary_id>2010-024579-23</secondary_id>
    <nct_id>NCT01464307</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke</brief_title>
  <acronym>PLUS</acronym>
  <official_title>Prospective, Double-blind, Placebo-controlled, Randomized, Multi-center Study With an Open-label Extension Period to Investigate the Efficacy and Safety of NT 201 in the Treatment of Post-stroke Spasticity of the Lower Limb</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merz Pharmaceuticals GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merz Pharmaceuticals GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether injections of Botulinum toxin type A into
      muscles of the leg are effective in treating patients with increased muscle
      tension/uncontrollable muscle stiffness (spasticity) after a stroke.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Ashworth Scale (AS) for Plantar Flexors at Week 4</measure>
    <time_frame>Baseline and Week 4</time_frame>
    <description>The AS is a well known and commonly used scale in clinical trials with spasticity. It was considered to be the best clinical tool for measuring resistance to movement. It was used to categorize the severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Co-primary Variable: Investigator's Global Assessment of Efficacy at Week 12</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>A 4-point Likert scale will be used with the ratings 1 = very good, 2 = good, 3 = moderate, and 4 = poor. Investigator's Global Assessment of Efficacy at Week 12 will be a co-primary outcome measure to fulfill post marketing commitments for U.S. regulatory authorities only. Elsewhere, it will be a secondary outcome measure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response Rate for Plantar Flexors at All Post-Baseline Visits for Subjects With an Improvement (Reduction) of at Least 1 Point From Baseline in the Ashworth Scale (AS)</measure>
    <time_frame>Week 4, 8, and 12</time_frame>
    <description>Response is defined as an improvement (reduction) of the plantar flexor Ashworth Score by at least one score point. The AS is a well known and commonly used scale in clinical trials with spasticity. It was considered to be the best clinical tool for measuring resistance to movement. It was used to categorize the severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ashworth Scale (AS) for Plantar Flexors at All Post-Baseline Visits</measure>
    <time_frame>Baseline, Week 4, 8, and 12</time_frame>
    <description>The AS is a well known and commonly used scale in clinical trials with spasticity. It was considered to be the best clinical tool for measuring resistance to movement. It was used to categorize the severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Here, 'n' specifies those subjects who were evaluated for this outcome measure at given time point.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">290</enrollment>
  <condition>Post-stroke Spasticity of the Lower Limb</condition>
  <arm_group>
    <arm_group_label>IncobotulinumtoxinA (Xeomin) 400 Units</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IncobotulinumtoxinA (Xeomin, also known as &quot;NT 201&quot; or &quot;Botulinum toxin type A (150 kiloDalton), free from complexing proteins&quot;) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Comparator Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo to incobotulinumtoxinA (Xeomin) powder for solution for injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IncobotulinumtoxinA (400 Units)</intervention_name>
    <description>Main period: One injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), 400 units, total volume 8.0 mL; Mode of administration: intramuscular injection.</description>
    <arm_group_label>IncobotulinumtoxinA (Xeomin) 400 Units</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Comparator</intervention_name>
    <description>Main period: one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl, corresponding total placebo volume 8.0 mL; Mode of administration: intramuscular injection</description>
    <arm_group_label>Placebo Comparator Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age from 18-80 yrs

          -  Lower limb spasticity

          -  Time since stroke greater than 3 months

          -  Need for 400 U Botulinum toxin type A

        Exclusion Criteria:

          -  Body weight below 50kg

          -  Fixed contractures of the lower limb

          -  Generalized disorders of muscle activity like Myasthenia gravis that preclude use of
             Botulinum toxin type A

          -  Infection at the injection site
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Expert</last_name>
    <role>Study Director</role>
    <affiliation>Merz Pharmaceuticals GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Merz Investigational Site #001184</name>
      <address>
        <city>Downey</city>
        <state>California</state>
        <zip>90242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #001208</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #001244</name>
      <address>
        <city>Fairfield</city>
        <state>Connecticut</state>
        <zip>06824</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational site #001188</name>
      <address>
        <city>Doral</city>
        <state>Florida</state>
        <zip>33172</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site # 001110</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #001209</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #001210</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #001198</name>
      <address>
        <city>Stratford</city>
        <state>New Jersey</state>
        <zip>08084</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #001207</name>
      <address>
        <city>Plainview</city>
        <state>New York</state>
        <zip>11803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #001009</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #001206</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #001183</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #001204</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 4K4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #001202</name>
      <address>
        <city>Winnipeg</city>
        <zip>MB R3A 1M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #420024</name>
      <address>
        <city>Ostrava-Poruba</city>
        <zip>70852</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #420031</name>
      <address>
        <city>Ostrava-Vitkovice</city>
        <zip>70384</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #420030</name>
      <address>
        <city>Praha</city>
        <zip>12000</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #420047</name>
      <address>
        <city>Rychnov nad Kneznou</city>
        <zip>51601</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #033018</name>
      <address>
        <city>Garches</city>
        <zip>92380</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #033024</name>
      <address>
        <city>Rennes</city>
        <zip>35043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #049022</name>
      <address>
        <city>Beelitz-Heilstätten</city>
        <zip>14547</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #049071</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #049079</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #049304</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #049072</name>
      <address>
        <city>München</city>
        <zip>80804</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #049148</name>
      <address>
        <city>München</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #049303</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #049302</name>
      <address>
        <city>Würzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #039006</name>
      <address>
        <city>Messina</city>
        <zip>98125</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #039011</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #039012</name>
      <address>
        <city>Roma</city>
        <zip>00189</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #048057</name>
      <address>
        <city>Gdansk</city>
        <zip>80-462</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #048044</name>
      <address>
        <city>Kielce</city>
        <zip>25-103</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #048080</name>
      <address>
        <city>Krakow</city>
        <zip>30-349</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #048054</name>
      <address>
        <city>Krakow</city>
        <zip>30-510</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #048031</name>
      <address>
        <city>Krakow</city>
        <zip>31-505</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #048022</name>
      <address>
        <city>Lodz</city>
        <zip>90-130</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #048051</name>
      <address>
        <city>Lublin</city>
        <zip>20-022</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #048053</name>
      <address>
        <city>Poznan</city>
        <zip>61-485</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #048081</name>
      <address>
        <city>Poznan</city>
        <zip>61-853</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #048055</name>
      <address>
        <city>Warszawa</city>
        <zip>01-697</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #048023</name>
      <address>
        <city>Warszawa</city>
        <zip>02-957</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #048056</name>
      <address>
        <city>Warszawa</city>
        <zip>02097</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #048033</name>
      <address>
        <city>Warszawa</city>
        <zip>04-749</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #007010</name>
      <address>
        <city>Krasnoyarsk</city>
        <zip>660037</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #007011</name>
      <address>
        <city>Moscow</city>
        <zip>105005</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #007009</name>
      <address>
        <city>St. Petersburg</city>
        <zip>129019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #007012</name>
      <address>
        <city>Stavropol</city>
        <zip>355000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #034027</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #034028</name>
      <address>
        <city>Majadahonda</city>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #034026</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #034030</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #034029</name>
      <address>
        <city>Terrassa</city>
        <zip>08221</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Austria</country>
  </removed_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 2011</study_first_submitted>
  <study_first_submitted_qc>November 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2011</study_first_posted>
  <results_first_submitted>July 26, 2016</results_first_submitted>
  <results_first_submitted_qc>November 4, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 7, 2016</results_first_posted>
  <disposition_first_submitted>July 31, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>July 31, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 21, 2015</disposition_first_posted>
  <last_update_submitted>November 4, 2016</last_update_submitted>
  <last_update_submitted_qc>November 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Muscle Spasticity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>onabotulinumtoxinA</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
    <mesh_term>incobotulinumtoxinA</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 331 individuals suffering from post-stroke lower-limb spasticity were screened and 290 were included in study at 51 sites. One ineligible subject was randomized to placebo but withdrawn from study prior to first treatment with study medication. For purpose of study analysis overall number of subjects enrolled is therefore considered 289.</recruitment_details>
      <pre_assignment_details>A total of 290 subjects were enrolled in study. One ineligible subject was randomized to placebo but withdrawn from study prior to first treatment with study medication. A total of 289 subjects were enrolled in main period. All of the 269 subjects who completed the main period of the study entered the open-label extension period.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>IncobotulinumtoxinA (Xeomin) 400 Units</title>
          <description>IncobotulinumtoxinA (Xeomin, also known as &quot;NT 201&quot; or &quot;Botulinum toxin type A (150 kiloDalton), free from complexing proteins&quot;) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection.
IncobotulinumtoxinA (400 Units): Main period: One injection session of solution, prepared by reconstitution of powder with 0.9 percent (%) Sodium Chloride (NaCl), 400 units, total volume 8.0 milliliter (mL); Mode of administration: intramuscular injection.
IncobotulinumtoxinA (400 Units): Open-Label Extension Period: All subjects receive three injection sessions of solution, prepared by reconstitution of powder with 0.9% NaCl, 400 units, total volume 8.0 mL; Mode of administration: intramuscular injection.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo to incobotulinumtoxinA (Xeomin) powder for solution for injection.
Placebo Comparator: Main period: one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl, corresponding total placebo volume 8.0 mL; Mode of administration: intramuscular injection</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Main Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="144"/>
                <participants group_id="P2" count="145"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="144"/>
                <participants group_id="P2" count="145"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="129"/>
                <participants group_id="P2" count="140"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Predefined discontinuation criteria</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Open-Label Extension Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="269"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="269"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="218"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Predefined discontinuation criteria</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The Safety Evaluation Set (SES) is the subset of all subjects who were exposed to Investigational product (IP) in the main period at least once.</population>
      <group_list>
        <group group_id="B1">
          <title>Main Period: IncobotulinumtoxinA (Xeomin) 400 Units</title>
          <description>IncobotulinumtoxinA (Xeomin, also known as &quot;NT 201&quot; or &quot;Botulinum toxin type A (150 kiloDalton), free from complexing proteins&quot;) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection.
IncobotulinumtoxinA (400 Units): Main period: One injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), 400 units, total volume 8.0 mL; Mode of administration: intramuscular injection.</description>
        </group>
        <group group_id="B2">
          <title>Main Period: Placebo</title>
          <description>Placebo to incobotulinumtoxinA (Xeomin) powder for solution for injection.
Placebo Comparator: Main period: one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl, corresponding total placebo volume 8.0 mL; Mode of administration: intramuscular injection</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="144"/>
            <count group_id="B2" value="145"/>
            <count group_id="B3" value="289"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.3" spread="11.2"/>
                    <measurement group_id="B2" value="57.0" spread="13.0"/>
                    <measurement group_id="B3" value="57.2" spread="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="95"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="104"/>
                    <measurement group_id="B2" value="90"/>
                    <measurement group_id="B3" value="194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Ashworth Scale (AS) for Plantar Flexors at Week 4</title>
        <description>The AS is a well known and commonly used scale in clinical trials with spasticity. It was considered to be the best clinical tool for measuring resistance to movement. It was used to categorize the severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension).</description>
        <time_frame>Baseline and Week 4</time_frame>
        <population>The Full Analysis Set (FAS) included subjects in the Safety Evaluation Set (SES) of the main period for whom the primary efficacy variable was available, whereby SES is the subset of all subjects who were exposed to IP in the main period at least once.</population>
        <group_list>
          <group group_id="O1">
            <title>IncobotulinumtoxinA (Xeomin) 400 Units</title>
            <description>IncobotulinumtoxinA (Xeomin, also known as &quot;NT 201&quot; or &quot;Botulinum toxin type A (150 kiloDalton), free from complexing proteins&quot;) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection.
IncobotulinumtoxinA (400 Units): Main period: One injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), 400 units, total volume 8.0 mL; Mode of administration: intramuscular injection.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to incobotulinumtoxinA (Xeomin) powder for solution for injection.
Placebo Comparator: Main period: one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl, corresponding total placebo volume 8.0 mL; Mode of administration: intramuscular injection</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Ashworth Scale (AS) for Plantar Flexors at Week 4</title>
          <description>The AS is a well known and commonly used scale in clinical trials with spasticity. It was considered to be the best clinical tool for measuring resistance to movement. It was used to categorize the severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension).</description>
          <population>The Full Analysis Set (FAS) included subjects in the Safety Evaluation Set (SES) of the main period for whom the primary efficacy variable was available, whereby SES is the subset of all subjects who were exposed to IP in the main period at least once.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="0.7"/>
                    <measurement group_id="O2" value="2.8" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="0.7"/>
                    <measurement group_id="O2" value="-0.4" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The number of subjects included in the MMRM analysis was only 286 because a covariate was missing for 3 subjects.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.777</p_value>
            <method>Mixed-Model Repeated Measures</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.1</ci_lower_limit>
            <ci_upper_limit>0.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Co-primary Variable: Investigator's Global Assessment of Efficacy at Week 12</title>
        <description>A 4-point Likert scale will be used with the ratings 1 = very good, 2 = good, 3 = moderate, and 4 = poor. Investigator's Global Assessment of Efficacy at Week 12 will be a co-primary outcome measure to fulfill post marketing commitments for U.S. regulatory authorities only. Elsewhere, it will be a secondary outcome measure.</description>
        <time_frame>Baseline to Week 12</time_frame>
        <population>The Full Analysis Set (FAS) included subjects in the Safety Evaluation Set (SES) of the main period for whom the primary efficacy variable was available, whereby SES is the subset of all subjects who were exposed to IP in the main period at least once.</population>
        <group_list>
          <group group_id="O1">
            <title>IncobotulinumtoxinA (Xeomin) 400 Units</title>
            <description>IncobotulinumtoxinA (Xeomin, also known as &quot;NT 201&quot; or &quot;Botulinum toxin type A (150 kiloDalton), free from complexing proteins&quot;) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection.
IncobotulinumtoxinA (400 Units): Main period: One injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), 400 units, total volume 8.0 mL; Mode of administration: intramuscular injection.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to incobotulinumtoxinA (Xeomin) powder for solution for injection.
Placebo Comparator: Main period: one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl, corresponding total placebo volume 8.0 mL; Mode of administration: intramuscular injection</description>
          </group>
        </group_list>
        <measure>
          <title>Co-primary Variable: Investigator's Global Assessment of Efficacy at Week 12</title>
          <description>A 4-point Likert scale will be used with the ratings 1 = very good, 2 = good, 3 = moderate, and 4 = poor. Investigator's Global Assessment of Efficacy at Week 12 will be a co-primary outcome measure to fulfill post marketing commitments for U.S. regulatory authorities only. Elsewhere, it will be a secondary outcome measure.</description>
          <population>The Full Analysis Set (FAS) included subjects in the Safety Evaluation Set (SES) of the main period for whom the primary efficacy variable was available, whereby SES is the subset of all subjects who were exposed to IP in the main period at least once.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Very good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5"/>
                    <measurement group_id="O2" value="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.5"/>
                    <measurement group_id="O2" value="22.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.2"/>
                    <measurement group_id="O2" value="26.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.8"/>
                    <measurement group_id="O2" value="45.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The statistical analysis provided was for all categories of this outcome measure.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.804</p_value>
            <p_value_desc>worst-case analysis.</p_value_desc>
            <method>Wilcoxon's Rank-Sum Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response Rate for Plantar Flexors at All Post-Baseline Visits for Subjects With an Improvement (Reduction) of at Least 1 Point From Baseline in the Ashworth Scale (AS)</title>
        <description>Response is defined as an improvement (reduction) of the plantar flexor Ashworth Score by at least one score point. The AS is a well known and commonly used scale in clinical trials with spasticity. It was considered to be the best clinical tool for measuring resistance to movement. It was used to categorize the severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension).</description>
        <time_frame>Week 4, 8, and 12</time_frame>
        <population>The FAS included subjects in SES of main period for whom primary efficacy variable was available, whereby SES is subset of all subjects who were exposed to IP in main period at least once. Here, “N”(Number of Participants Analyzed) and &quot;n&quot; signifies those participants who were evaluable for this outcome measure and at given time point respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>IncobotulinumtoxinA (Xeomin) 400 Units</title>
            <description>IncobotulinumtoxinA (Xeomin, also known as &quot;NT 201&quot; or &quot;Botulinum toxin type A (150 kiloDalton), free from complexing proteins&quot;) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection.
IncobotulinumtoxinA (400 Units): Main period: One injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), 400 units, total volume 8.0 mL; Mode of administration: intramuscular injection.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to incobotulinumtoxinA (Xeomin) powder for solution for injection.
Placebo Comparator: Main period: one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl, corresponding total placebo volume 8.0 mL; Mode of administration: intramuscular injection</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate for Plantar Flexors at All Post-Baseline Visits for Subjects With an Improvement (Reduction) of at Least 1 Point From Baseline in the Ashworth Scale (AS)</title>
          <description>Response is defined as an improvement (reduction) of the plantar flexor Ashworth Score by at least one score point. The AS is a well known and commonly used scale in clinical trials with spasticity. It was considered to be the best clinical tool for measuring resistance to movement. It was used to categorize the severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension).</description>
          <population>The FAS included subjects in SES of main period for whom primary efficacy variable was available, whereby SES is subset of all subjects who were exposed to IP in main period at least once. Here, “N”(Number of Participants Analyzed) and &quot;n&quot; signifies those participants who were evaluable for this outcome measure and at given time point respectively.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="144"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4 (n=142, 144)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.3"/>
                    <measurement group_id="O2" value="35.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=140, 142)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.3"/>
                    <measurement group_id="O2" value="33.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=135, 141)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 4. Number of subjects included in analysis was three less than the observed cases because of a missing covariate for the logistic regression analysis, that is, n=283 for week 4.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.845</p_value>
            <p_value_desc>observed cases analysis.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.63</ci_lower_limit>
            <ci_upper_limit>1.74</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 8. Number of subjects included in analysis was three less than the observed cases because of a missing covariate for the logistic regression analysis, that is, n=279 for week 8.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.437</p_value>
            <p_value_desc>observed cases analysis.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.73</ci_lower_limit>
            <ci_upper_limit>2.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 12. Number of subjects included in analysis was three less than the observed cases because of a missing covariate for the logistic regression analysis, that is, n=273 for week 12.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.698</p_value>
            <p_value_desc>observed cases analysis.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.59</ci_lower_limit>
            <ci_upper_limit>2.21</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ashworth Scale (AS) for Plantar Flexors at All Post-Baseline Visits</title>
        <description>The AS is a well known and commonly used scale in clinical trials with spasticity. It was considered to be the best clinical tool for measuring resistance to movement. It was used to categorize the severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Here, ‘n’ specifies those subjects who were evaluated for this outcome measure at given time point.</description>
        <time_frame>Baseline, Week 4, 8, and 12</time_frame>
        <population>The Full Analysis Set (FAS) included subjects in the Safety Evaluation Set (SES) of the main period for whom the primary efficacy variable was available, whereby SES is the subset of all subjects who were exposed to IP in the main period at least once.</population>
        <group_list>
          <group group_id="O1">
            <title>IncobotulinumtoxinA (Xeomin) 400 Units</title>
            <description>IncobotulinumtoxinA (Xeomin, also known as &quot;NT 201&quot; or &quot;Botulinum toxin type A (150 kiloDalton), free from complexing proteins&quot;) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection.
IncobotulinumtoxinA (400 Units): Main period: One injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), 400 units, total volume 8.0 mL; Mode of administration: intramuscular injection.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to incobotulinumtoxinA (Xeomin) powder for solution for injection.
Placebo Comparator: Main period: one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl, corresponding total placebo volume 8.0 mL; Mode of administration: intramuscular injection</description>
          </group>
        </group_list>
        <measure>
          <title>Ashworth Scale (AS) for Plantar Flexors at All Post-Baseline Visits</title>
          <description>The AS is a well known and commonly used scale in clinical trials with spasticity. It was considered to be the best clinical tool for measuring resistance to movement. It was used to categorize the severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Here, ‘n’ specifies those subjects who were evaluated for this outcome measure at given time point.</description>
          <population>The Full Analysis Set (FAS) included subjects in the Safety Evaluation Set (SES) of the main period for whom the primary efficacy variable was available, whereby SES is the subset of all subjects who were exposed to IP in the main period at least once.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=144, 145)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="0.7"/>
                    <measurement group_id="O2" value="2.8" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n= 142, 144)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="0.9"/>
                    <measurement group_id="O2" value="2.4" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=140, 142)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="0.9"/>
                    <measurement group_id="O2" value="2.5" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n= 135, 141)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="0.8"/>
                    <measurement group_id="O2" value="2.7" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From time point of first injection until 120 +/- 7 days after last administration of injection</time_frame>
      <desc>The investigator asked the subject for adverse events systematically at each visit.</desc>
      <group_list>
        <group group_id="E1">
          <title>Main Period: IncobotulinumtoxinA (Xeomin) 400 Units</title>
          <description>IncobotulinumtoxinA (Xeomin, also known as &quot;NT 201&quot; or &quot;Botulinum toxin type A (150 kiloDalton), free from complexing proteins&quot;) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection.
IncobotulinumtoxinA (400 Units): Main period: One injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), 400 units, total volume 8.0 mL; Mode of administration: intramuscular injection.</description>
        </group>
        <group group_id="E2">
          <title>Main Period: Placebo</title>
          <description>Placebo to incobotulinumtoxinA (Xeomin) powder for solution for injection.
Placebo Comparator: Main period: one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl, corresponding total placebo volume 8.0 mL; Mode of administration: intramuscular injection</description>
        </group>
        <group group_id="E3">
          <title>Open-Label Extension: IncobotulinumtoxinA (Xeomin) 400 Units</title>
          <description>IncobotulinumtoxinA (Xeomin, also known as &quot;NT 201&quot; or &quot;Botulinum toxin type A (150 kiloDalton), free from complexing proteins&quot;) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection.
IncobotulinumtoxinA (400 Units): Open-Label Extension Period: All subjects receive three injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), 400 units, total volume 8.0 mL; Mode of administration: intramuscular injection.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="145"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Haemolytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Jaundice cholestatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Fractured sacrum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Face injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Upper-limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Mobility decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Pancreatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Desmoid tumour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Intracranial haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Personality disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Uterine polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Immobile</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cranioplasty</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Medical induction of coma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Skin lesion excision</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Tracheostomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Limb operation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Rehabilitation therapy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="145"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="145"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="145"/>
                <counts group_id="E3" events="12" subjects_affected="11" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>γ-glutamyltransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="144"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="145"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="145"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Publication of study information usually requires agreement with the sponsor. In case of justified doubts by the sponsor, the Investigator will consider these doubts in the publication as long as the scientific neutrality is not affected.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Public Disclosure Manager</name_or_title>
      <organization>Merz Pharmaceuticals GmbH</organization>
      <phone>+49 69 1503 1</phone>
      <email>clinicaltrials@merz.de</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

